EyeGate Pharmaceuticals, Inc. (EYEG) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $0.40, up from yesterday’s close by 12.76%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.Fundamental Analysis
EyeGate Pharmaceuticals, Inc. (EYEG) currently trades with a market capitalization of $7.44 Million. That value represents a market adjusting for revenues that have been falling by -100.00 % on a quarterly year/year basis as of the company’s last quarterly report.
You can get a sense of how sustainable that is by a levered free cash flow of -$6.49 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of -$0.24 on a per share basis this quarter. Perhaps, that suggests something about why 4.24% of the outstanding share supply is held by institutional investors.
It’s important to check the technicals to get a sense of how EYEG has been acting. Looking at the stock’s movement on the chart, EyeGate Pharmaceuticals, Inc. recorded a 52-week high of $2.43. It is now trading 2.03% off that level. The stock is trading $0.54 its 50-day moving average by 0.14%. The stock carved out a 52-week low down at $0.29.
In recent action, EyeGate Pharmaceuticals, Inc. (EYEG) has made a move of -34.43% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 13.41, and it’s gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 3.15% with $16.50 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of EYEG.